FindTrial
Sign In

Multi-center clinical study of multiparametric MRI radiomics immunophenotyping ProMI model in predicting responsiveness to immunotherapy in prostate cancer

Multi-center clinical study of multiparametric MRI radiomics immunophenotyping ProMI model in predicting responsiveness to immunotherapy in prostate cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056899
Enrollment
Unknown
Registered
2022-02-22
Start date
2022-03-14
Completion date
Unknown
Last updated
2023-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

case series:NA

Sponsors

Sun Yat-Sen Memorial Hosipital of Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1. No age limit; 2. Multi-parameter MRI data of prostate before puncture or radical surgery can be provided; 3. Can provide prostate cancer pathological white slices for immunohistochemical detection; 4. Can provide prostate cancer tissue mRNA for transcriptome sequencing; 5. Prostatic vesicular adenocarcinoma or ductal adenocarcinoma is predominant (more than 50%), without neuroendocrine tumors.

Exclusion criteria

Exclusion criteria: The mRNA quality of prostate cancer tissue is not good.

Design outcomes

Primary

MeasureTime frame
Imaging progression-free survival after immunotherapy in patients with high and low immune status;—

Secondary

MeasureTime frame
Overall survival rate;Objective response rate;—

Countries

China

Contacts

Public ContactHuang Hai
huanghai257@126.com+86 13711502580

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026